FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277778922> ?p ?o ?g. }

• W2277778922 endingPage "15155" @default.
• W2277778922 startingPage "15155" @default.
• W2277778922 abstract "15155 Background: Phase I data show that low levels of electromagnetic fields modulated at specific frequencies administered intrabucally with the THERABIONIC device are a safe and potentially effective treatment for advanced cancer. The device emits a 27.12 MHz radiofrequency signal, amplitude-modulated at tumor-specific frequencies ranging from 0.2 to 23,000 Hz. The device is connected to a spoon- like coupler placed in the patient’s mouth during treatment. Patients with advanced HCC and limited therapeutic options were offered treatment with HCC-specific frequencies. Methods: From October 2005 to October 2006, 38 patients with advanced HCC were recruited in a phase II study. The patients received three daily 40 min treatments until disease progression or death. The median age was 64.0 ± 14.2 years. 32 patients were male and 29 patients had documented progression of disease (POD) by IV contrast imaging prior to study entry. 8 patients had not received prior therapy because of metastases (3), poor medical condition (3), declined chemotherapy (2). Results: As of January 2007, 12 patients are still on therapy, 20 patients died of tumor progression, 2 patients are lost to follow-up and 3 patients withdrew consent. 27 patients are eligible for response. The overall objective response rate as defined by partial response (PR) or stable disease (SD) in patients with prior documented POD was 31.6%: 3 PR and 9 SD. The median survival was 20.7 weeks with a median duration of therapy of 17.5 weeks. 13 patients have received therapy for more than six months. The median duration of response is 12.9 weeks. 12 patients reported pain at study entry: 8 of them (66%) experienced decreased pain during treatment. There were no NCI grade 2/3/4 toxicities. One patient had grade 1 mucositis and grade 1 fatigue. Conclusion: In patients with advanced HCC, THERABIONIC is a safe and effective novel therapeutic option, which has significant anti-tumor effect and provides pain relief in the majority of patients. [Table: see text] No significant financial relationships to disclose." @default.
• W2277778922 created "2016-06-24" @default.
• W2277778922 creator A5000048844 @default.
• W2277778922 creator A5004949723 @default.
• W2277778922 creator A5013398330 @default.
• W2277778922 creator A5037353093 @default.
• W2277778922 creator A5041268459 @default.
• W2277778922 creator A5042254050 @default.
• W2277778922 creator A5056984998 @default.
• W2277778922 creator A5091831306 @default.
• W2277778922 date "2007-06-20" @default.
• W2277778922 modified "2023-09-24" @default.
• W2277778922 title "A phase II study of amplitude-modulated electromagnetic fields in the treatment of advanced hepatocellular carcinoma (HCC)" @default.
• W2277778922 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15155" @default.
• W2277778922 hasPublicationYear "2007" @default.
• W2277778922 type Work @default.
• W2277778922 sameAs 2277778922 @default.
• W2277778922 citedByCount "6" @default.
• W2277778922 countsByYear W22777789222016 @default.
• W2277778922 countsByYear W22777789222019 @default.
• W2277778922 countsByYear W22777789222021 @default.
• W2277778922 countsByYear W22777789222022 @default.
• W2277778922 crossrefType "journal-article" @default.
• W2277778922 hasAuthorship W2277778922A5000048844 @default.
• W2277778922 hasAuthorship W2277778922A5004949723 @default.
• W2277778922 hasAuthorship W2277778922A5013398330 @default.
• W2277778922 hasAuthorship W2277778922A5037353093 @default.
• W2277778922 hasAuthorship W2277778922A5041268459 @default.
• W2277778922 hasAuthorship W2277778922A5042254050 @default.
• W2277778922 hasAuthorship W2277778922A5056984998 @default.
• W2277778922 hasAuthorship W2277778922A5091831306 @default.
• W2277778922 hasConcept C121608353 @default.
• W2277778922 hasConcept C126322002 @default.
• W2277778922 hasConcept C141071460 @default.
• W2277778922 hasConcept C2776694085 @default.
• W2277778922 hasConcept C2778019345 @default.
• W2277778922 hasConcept C31760486 @default.
• W2277778922 hasConcept C71924100 @default.
• W2277778922 hasConcept C90924648 @default.
• W2277778922 hasConceptScore W2277778922C121608353 @default.
• W2277778922 hasConceptScore W2277778922C126322002 @default.
• W2277778922 hasConceptScore W2277778922C141071460 @default.
• W2277778922 hasConceptScore W2277778922C2776694085 @default.
• W2277778922 hasConceptScore W2277778922C2778019345 @default.
• W2277778922 hasConceptScore W2277778922C31760486 @default.
• W2277778922 hasConceptScore W2277778922C71924100 @default.
• W2277778922 hasConceptScore W2277778922C90924648 @default.
• W2277778922 hasIssue "18_suppl" @default.
• W2277778922 hasLocation W22777789221 @default.
• W2277778922 hasOpenAccess W2277778922 @default.
• W2277778922 hasPrimaryLocation W22777789221 @default.
• W2277778922 hasRelatedWork W113810927 @default.
• W2277778922 hasRelatedWork W1586374228 @default.
• W2277778922 hasRelatedWork W2003938723 @default.
• W2277778922 hasRelatedWork W2047967234 @default.
• W2277778922 hasRelatedWork W2118496982 @default.
• W2277778922 hasRelatedWork W2364998975 @default.
• W2277778922 hasRelatedWork W2369162477 @default.
• W2277778922 hasRelatedWork W2439875401 @default.
• W2277778922 hasRelatedWork W4238867864 @default.
• W2277778922 hasRelatedWork W2525756941 @default.
• W2277778922 hasVolume "25" @default.
• W2277778922 isParatext "false" @default.
• W2277778922 isRetracted "false" @default.
• W2277778922 magId "2277778922" @default.
• W2277778922 workType "article" @default.